Time to disability milestones and annualized relapse rates in NMOSD and MOGAD
A Duchow, J Bellmann‐Strobl, T Friede… - Annals of …, 2024 - Wiley Online Library
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
Time to disability milestones and annualized relapse rates in NMOSD and MOGAD
A Duchow, J Bellmann‐Strobl, T Friede, O Aktas… - 2023 - publications.goettingen-research …
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann‐strobl, T Friede… - Annals of …, 2024 - cnrs.hal.science
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann-Strobl, T Friede… - Annals of …, 2024 - pubmed.ncbi.nlm.nih.gov
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) …
Time to disability milestones and annualized relapse rates in NMOSD and MOGAD
A Duchow, J Bellmann-Strobl, T Friede… - Annals of …, 2024 - edoc.mdc-berlin.de
OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum
disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease …
disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease …
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann‐strobl, T Friede, O Aktas… - Annals of …, 2024 - hal.science
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann‐strobl, T Friede… - Annals of …, 2024 - amu.hal.science
Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) …
[引用][C] Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann-Strobl, T Friede, O Aktas… - 2024 - oparu.uni-ulm.de
[PDF][PDF] Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
A Duchow, J Bellmann-Strobl, T Friede, O Aktas… - 2023 - researchgate.net
Objective: To investigate accumulation of disability in neuromyelitis optica spectrum disorder
(NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) …
(NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) …
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
A Duchow, J Bellmann-Strobl, T Friede, O Aktas… - 2024 - mediatum.ub.tum.de
OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum
disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease …
disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease …